CN112546072A - 一种脂质体包裹人干细胞混悬液的制备方法 - Google Patents
一种脂质体包裹人干细胞混悬液的制备方法 Download PDFInfo
- Publication number
- CN112546072A CN112546072A CN202011644831.4A CN202011644831A CN112546072A CN 112546072 A CN112546072 A CN 112546072A CN 202011644831 A CN202011644831 A CN 202011644831A CN 112546072 A CN112546072 A CN 112546072A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- cells
- culture medium
- liposome
- mesenchymal stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 17
- 239000006285 cell suspension Substances 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 33
- 239000002502 liposome Substances 0.000 claims abstract description 30
- 239000000725 suspension Substances 0.000 claims abstract description 28
- 210000003954 umbilical cord Anatomy 0.000 claims abstract description 24
- 239000012228 culture supernatant Substances 0.000 claims abstract description 20
- 238000004113 cell culture Methods 0.000 claims abstract description 13
- 239000006228 supernatant Substances 0.000 claims abstract description 12
- 102000000802 Galectin 3 Human genes 0.000 claims abstract description 11
- 108010001517 Galectin 3 Proteins 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 9
- 230000001506 immunosuppresive effect Effects 0.000 claims abstract description 8
- 238000002965 ELISA Methods 0.000 claims abstract description 6
- 208000032544 Cicatrix Diseases 0.000 claims abstract description 3
- 231100000241 scar Toxicity 0.000 claims abstract description 3
- 230000037387 scars Effects 0.000 claims abstract description 3
- 230000037303 wrinkles Effects 0.000 claims abstract description 3
- 239000001963 growth medium Substances 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 28
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 10
- 235000012000 cholesterol Nutrition 0.000 claims description 10
- 239000000839 emulsion Substances 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 150000003904 phospholipids Chemical class 0.000 claims description 10
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 10
- 229920000053 polysorbate 80 Polymers 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 102000029816 Collagenase Human genes 0.000 claims description 6
- 108060005980 Collagenase Proteins 0.000 claims description 6
- 229960002424 collagenase Drugs 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 5
- 210000004748 cultured cell Anatomy 0.000 claims description 5
- 239000012894 fetal calf serum Substances 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000002390 rotary evaporation Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 230000003068 static effect Effects 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 4
- 239000002953 phosphate buffered saline Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 229960001484 edetic acid Drugs 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种脂质体包裹人干细胞混悬液的制备方法。本发明采用先分别制备的间充质干细胞培养液上清液和空白脂质体悬液混合,然后制得含间充质脂质体干细胞的脂质体混悬液,最后采用ELISA方法检测脐带间充质干细胞培养上清液中galectin‑3的含量来判断其免疫抑制效力。本发明在较短的培养时间内得到大量的人间充质干细胞,缩短了总的培养时间,可以用于治疗皮肤皱纹、色斑和瘢痕。
Description
技术领域
本发明属于干细胞活性复合制剂技术领域,尤其涉及一种用于美容护肤的干细胞活性复合制剂及其制备方法。
背景技术
间充质干细胞(MSC)是一类早期未分化细胞,具有自我更新、自我复制、无限增殖及多向分化潜能等特点,可通过分泌细胞因子,减少炎症、减少组织细胞凋亡、促进内源性组织器官的干祖细胞增殖及进行免疫调节,从而作为种子细胞达到修复组织器官的效果。连续传代培养和冷冻保存后仍具有多向分化潜能,医学界称为“万用细胞”。由于其免疫原性较低,细胞含量高、增殖能力优等特点,被广泛应用于美容整形等领域。人间充质干细胞培养基上清,是人体间充质干细胞在增殖过程中,经过特殊培养后分泌出的多种生命活性物质,包括蛋白质、多肽、细胞生长因子等促进细胞生长、活化,再生等活性因子,经过特殊的分离提取工艺和加工手段,将其中的多种有效活性成分经过检验制备而成,使用一些常规方法,例如机械摩擦、紫外线照射和饥饿培养等方案,并不能显著提高干细胞上清中因子的含量。此外,浓缩后的细胞培养基中,各种因子会在短时间内迅速降解和失活。
发明内容
本发明的主要目的是为了解决现有技术中的缺陷,提供一种脂质体包裹人干细胞混悬液的制备方法,本发明的方法诱导效率高、干细胞因子产量大,可短时间内获得大量的干细胞因子。
为达到上述发明目的,本发明通过以下技术方案来实现:
第一步、取清洗干净的脐带碎块,向50ml离心管中加入5ml脐带碎块和20ml2毫克/ml胶原酶IV,在37℃摇床上消化1.5-2小时,每管加入完全培养基到45ml刻度,在2200转/分离心10分钟,其中,完全培养基为DMEM/F12,并按体积比加入2%胎牛血清,培养条件为37℃,饱和湿度,5%CO2培养箱中静止培养,弃除上悬液,再将每个离心管中分散的细胞悬浮于40ml完全培养基中,每3天更换一次完全培养液,再使用磷酸盐缓冲盐水清洗培养的细胞2次,质量百分数为0.25%胰酶-EDTA消化,待细胞悬浮后加入2.5ml5%FBS培养基,在1000转/分离心10分钟,再悬浮于总量40ml质量百分数为5%FBS培养基,每3天换一次5%FBS培养基,培养细胞直到长满90%面积,从此开始收集培养上清液,冻存在-20℃,得间充质干细胞培养液上清液;第二步、将磷脂、胆固醇、吐温-80和抗氧化剂溶于无水乙醇中,其中,磷脂、胆固醇、吐温-80和抗氧化剂的总质量与无水乙醇的质量比为1∶3~1∶4,将混合特旋转蒸发,控制水浴温度35-40℃,旋转转速20~80r/min,真空度维持在0.010-0.020MPa,直至溶剂去除将薄膜洗下,得到乳浊液,再将乳浊液置搅拌30-50min,控制搅拌器温度为40-45℃,转速为60~100r/min,搅拌结束后再进行超声整粒,得到空白脂质体悬液;第三步:将上述制备的间充质干细胞培养液上清液和空白脂质体悬液混合,制得含间充质脂质体干细胞的脂质体混悬液。脂质体混悬液采用ELISA方法检测脐带间充质干细胞培养上清液中galectin-3的含量来判断其免疫抑制效力,人脐带间充质干细胞培养上清液中galectin-3的含量低于2.5ng/ml判定为人脐带间充质干细胞免疫抑制效力不合格,制得的干细胞混悬液可以用于治疗皮肤皱纹、色斑和瘢痕。
本发明公开的一种脂质体包裹人干细胞混悬液的制备方法的有益效果是:由于本发明本生产方法取材于健康人的脐带组织,胶原酶消化之后,经体外培养,在较短的培养时间内得到大量的人间充质干细胞(MSC),进一步收集得大量的MSC培养上清液,缩短了总的培养时间。
具体实施方式
实施例一
第一步、取清洗干净的脐带碎块,向50ml离心管中加入5ml脐带碎块和40mg胶原酶IV,在37℃摇床上消化1.5小时,每管加入完全培养基到45ml刻度,在2200转/分离心10分钟,其中,完全培养基为DMEM/F12,并按体积比加入2%胎牛血清,培养条件为37℃,饱和湿度,5%CO2培养箱中静止培养,弃除上悬液,再将每个离心管中分散的细胞悬浮于40ml完全培养基中,每3天更换一次完全培养液,再使用磷酸盐缓冲盐水清洗培养的细胞2次,质量百分数为0.5%胰酶-EDTA消化,待细胞悬浮后加入2.5ml5%FBS培养基,在1000转/分离心10分钟,再悬浮于总量40ml质量百分数为5%FBS培养基,每3天换一次5%FBS培养基,培养细胞直到长满90%面积,从此开始收集培养上清液,冻存在-20℃,得间充质干细胞培养液上清液;第二步、将磷脂、胆固醇、吐温-80和抗氧化剂溶于无水乙醇中,其中,磷脂、胆固醇、吐温-80和抗氧化剂的总质量与无水乙醇的质量比为1∶3,将混合特旋转蒸发,控制水浴温度35℃,旋转转速20r/min,真空度维持在0.01MPa,直至溶剂去除将薄膜洗下,得到乳浊液,再将乳浊液置搅拌30min,控制搅拌器温度为40℃,转速为60r/min,搅拌结束后再进行超声整粒,得到空白脂质体悬液;第三步:将上述制备的间充质干细胞培养液上清液和空白脂质体悬液混合,制得含间充质脂质体干细胞的脂质体混悬液。脂质体混悬液采用ELISA方法检测脐带间充质干细胞培养上清液中galectin-3的含量来判断其免疫抑制效力,本实例人脐带间充质干细胞培养上清液中galectin-3的含量为2ng/ml,低于2.5ng/ml判定标准。
实施例二
第一步、取清洗干净的脐带碎块,向50ml离心管中加入5ml脐带碎块和40mg胶原酶IV,在37℃摇床上消化2小时,每管加入完全培养基到45ml刻度,在2200转/分离心10分钟,其中,完全培养基为DMEM/F12,并按体积比加入2%胎牛血清,培养条件为37℃,饱和湿度,5%CO2培养箱中静止培养,弃除上悬液,再将每个离心管中分散的细胞悬浮于40ml完全培养基中,每3天更换一次完全培养液,再使用磷酸盐缓冲盐水清洗培养的细胞2次,质量百分数为0.5%胰酶-EDTA消化,待细胞悬浮后加入2.5ml5%FBS培养基,在1000转/分离心10分钟,再悬浮于总量40ml质量百分数为5%FBS培养基,每3天换一次5%FBS培养基,培养细胞直到长满90%面积,从此开始收集培养上清液,冻存在-20℃,得间充质干细胞培养液上清液;第二步、将磷脂、胆固醇、吐温-80和抗氧化剂溶于无水乙醇中,其中,磷脂、胆固醇、吐温-80和抗氧化剂的总质量与无水乙醇的质量比为1∶4,将混合特旋转蒸发,控制水浴温度40℃,旋转转速80r/min,真空度维持在0.02MPa,直至溶剂去除将薄膜洗下,得到乳浊液,再将乳浊液置搅拌50min,控制搅拌器温度为45℃,转速为100r/min,搅拌结束后再进行超声整粒,得到空白脂质体悬液;第三步:将上述制备的间充质干细胞培养液上清液和空白脂质体悬液混合,制得含间充质脂质体干细胞的脂质体混悬液。脂质体混悬液采用ELISA方法检测脐带间充质干细胞培养上清液中galectin-3的含量来判断其免疫抑制效力,脂质体混悬液采用ELISA方法检测脐带间充质干细胞培养上清液中galectin-3的含量来判断其免疫抑制效力,本实例人脐带间充质干细胞培养上清液中galectin-3的含量为1.8ng/ml,低于2.5ng/ml判定标准。
实施例三
第一步、取清洗干净的脐带碎块,向50ml离心管中加入5ml脐带碎块和40mg胶原酶IV,在37℃摇床上消化1.8小时,每管加入完全培养基到45ml刻度,在2200转/分离心10分钟,其中,完全培养基为DMEM/F12,并按体积比加入2%胎牛血清,培养条件为37℃,饱和湿度,5%CO2培养箱中静止培养,弃除上悬液,再将每个离心管中分散的细胞悬浮于40ml完全培养基中,每3天更换一次完全培养液,再使用磷酸盐缓冲盐水清洗培养的细胞2次,质量百分数为0.5%胰酶-EDTA消化,待细胞悬浮后加入2.5ml5%FBS培养基,在1000转/分离心10分钟,再悬浮于总量40ml质量百分数为5%FBS培养基,每3天换一次5%FBS培养基,培养细胞直到长满90%面积,从此开始收集培养上清液,冻存在-20℃,得间充质干细胞培养液上清液;第二步、将磷脂、胆固醇、吐温-80和抗氧化剂溶于无水乙醇中,其中,磷脂、胆固醇、吐温-80和抗氧化剂的总质量与无水乙醇的质量比为1∶3.5,将混合特旋转蒸发,控制水浴温度38℃,旋转转速50r/min,真空度维持在0.015MPa,直至溶剂去除将薄膜洗下,得到乳浊液,再将乳浊液置搅拌40min,控制搅拌器温度为42℃,转速为80r/min,搅拌结束后再进行超声整粒,得到空白脂质体悬液;第三步:将上述制备的间充质干细胞培养液上清液和空白脂质体悬液混合,制得含间充质脂质体干细胞的脂质体混悬液。脂质体混悬液采用ELISA方法检测脐带间充质干细胞培养上清液中galectin-3的含量来判断其免疫抑制效力,脂质体混悬液采用ELISA方法检测脐带间充质干细胞培养上清液中galectin-3的含量来判断其免疫抑制效力,本实例人脐带间充质干细胞培养上清液中galectin-3的含量为1.7ng/ml,低于2.5ng/ml判定标准。
Claims (3)
1.一种脂质体包裹人干细胞混悬液的制备方法,其特征在于:包含如下步骤:
第一步、取清洗干净的脐带碎块,向50毫升离心管中加入5毫升脐带碎块和20毫升2毫克/毫升胶原酶IV,在37℃摇床上消化1.5-2小时,每管加入完全培养基到45毫升刻度,在2200转/分离心10分钟,其中,完全培养基为DMEM/F12,并按体积比加入2%胎牛血清,培养条件为37℃,饱和湿度,5%CO2培养箱中静止培养,弃除上悬液,再将每个离心管中分散的细胞悬浮于40毫升完全培养基中,每3天更换一次完全培养液,再使用磷酸盐缓冲盐水清洗培养的细胞2次,质量百分数为0.25%胰酶-EDTA消化,待细胞悬浮后加入2.5毫升5%FBS培养基,在1000转/分离心10分钟,再悬浮于总量40毫升质量百分数为5%FBS培养基,每3天换一次5%FBS培养基,培养细胞直到长满90%面积,从此开始收集培养上清液,冻存在-20℃,得间充质干细胞培养液上清液;
第二步、将磷脂、胆固醇、吐温-80和抗氧化剂溶于无水乙醇中,其中,磷脂、胆固醇、吐温-80和抗氧化剂的总质量与无水乙醇的质量比为1∶3~1∶4,将混合特旋转蒸发,控制水浴温度35-40℃,旋转转速20~80r/min,真空度维持在0.010-0.020MPa,直至溶剂去除将薄膜洗下,得到乳浊液,再将乳浊液置搅拌30-50min,控制搅拌器温度为40-45℃,转速为60~100r/min,搅拌结束后再进行超声整粒,得到空白脂质体悬液;
第三步:将上述制备的间充质干细胞培养液上清液和空白脂质体悬液混合,制得含间充质脂质体干细胞的脂质体混悬液。
2.根据权利要求1所述的一种脂质体包裹人干细胞混悬液的制备方法,其特征在于所述的脂质体混悬液采用ELISA方法检测脐带间充质干细胞培养上清液中galectin-3的含量来判断其免疫抑制效力,人脐带间充质干细胞培养上清液中galectin-3的含量低于2.5ng/ml判定为人脐带间充质干细胞免疫抑制效力不合格。
3.根据权利要求1所述的一种脂质体包裹人干细胞混悬液的制备方法,期特征在于制得的干细胞混悬液可以用于治疗皮肤皱纹、色斑和瘢痕。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011644831.4A CN112546072A (zh) | 2020-12-24 | 2020-12-24 | 一种脂质体包裹人干细胞混悬液的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011644831.4A CN112546072A (zh) | 2020-12-24 | 2020-12-24 | 一种脂质体包裹人干细胞混悬液的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112546072A true CN112546072A (zh) | 2021-03-26 |
Family
ID=75035115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011644831.4A Pending CN112546072A (zh) | 2020-12-24 | 2020-12-24 | 一种脂质体包裹人干细胞混悬液的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112546072A (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102643909A (zh) * | 2012-04-05 | 2012-08-22 | 天津和泽干细胞科技有限公司 | 一种脐带间充质干细胞生物学效力的检测方法 |
JP2014214094A (ja) * | 2013-04-23 | 2014-11-17 | ファミセル カンパニー リミテッド | ヒト由来幹細胞培養液抽出物を包接させたリポソームを含有する化粧料組成物 |
CN104946585A (zh) * | 2015-07-07 | 2015-09-30 | 美天妮(天津)生物科技有限公司 | 一种人间充质干细胞培养液上清的生产方法及冻干方法及应用 |
CN104997652A (zh) * | 2015-07-09 | 2015-10-28 | 西安艾尔菲生物科技有限公司 | 一种抗皱保湿脂质体及其制备方法和应用 |
CN106176563A (zh) * | 2016-07-26 | 2016-12-07 | 西安艾尔菲生物科技有限公司 | 人脐带msc无血清培养液脂质体冻干粉及其制备和应用 |
CN108103016A (zh) * | 2018-02-26 | 2018-06-01 | 江苏蒙彼利生物科技有限公司 | 一种从脐带中提取间充质干细胞的制备方法 |
CN111374934A (zh) * | 2020-03-19 | 2020-07-07 | 厚朴生物科技(苏州)有限公司 | 脂质体包裹人干细胞因子的制备及皮肤损伤修复检测方法 |
-
2020
- 2020-12-24 CN CN202011644831.4A patent/CN112546072A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102643909A (zh) * | 2012-04-05 | 2012-08-22 | 天津和泽干细胞科技有限公司 | 一种脐带间充质干细胞生物学效力的检测方法 |
JP2014214094A (ja) * | 2013-04-23 | 2014-11-17 | ファミセル カンパニー リミテッド | ヒト由来幹細胞培養液抽出物を包接させたリポソームを含有する化粧料組成物 |
CN104946585A (zh) * | 2015-07-07 | 2015-09-30 | 美天妮(天津)生物科技有限公司 | 一种人间充质干细胞培养液上清的生产方法及冻干方法及应用 |
CN104997652A (zh) * | 2015-07-09 | 2015-10-28 | 西安艾尔菲生物科技有限公司 | 一种抗皱保湿脂质体及其制备方法和应用 |
CN106176563A (zh) * | 2016-07-26 | 2016-12-07 | 西安艾尔菲生物科技有限公司 | 人脐带msc无血清培养液脂质体冻干粉及其制备和应用 |
CN108103016A (zh) * | 2018-02-26 | 2018-06-01 | 江苏蒙彼利生物科技有限公司 | 一种从脐带中提取间充质干细胞的制备方法 |
CN111374934A (zh) * | 2020-03-19 | 2020-07-07 | 厚朴生物科技(苏州)有限公司 | 脂质体包裹人干细胞因子的制备及皮肤损伤修复检测方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102086451B (zh) | 一种皮肤组织工程种子细胞的扩增方法 | |
KR100907248B1 (ko) | 분화된 어린 지방 세포와 생분해성 중합체의 이식에 의한신체의 부피 대체 방법 | |
US20110217385A1 (en) | Method for extracting mesenchymal stem cell from human or animal embryo and for extracting the secretion product thereof | |
CN104946585A (zh) | 一种人间充质干细胞培养液上清的生产方法及冻干方法及应用 | |
US20220325247A1 (en) | METHOD FOR PROMOTING GROWTH OF PARIETAL DECIDUAL BASALIS-MESENCHYMAL STEM CELLS (PDB-MSCs) | |
CN105820998A (zh) | 临床回输级细胞治疗用人脂肪干细胞ADSCs分离提取培养方法 | |
CN110129392A (zh) | 一种脐带间充质干细胞因子的制备方法和用于制备干细胞精华液的用途 | |
CN108220230A (zh) | 一种人脂肪干细胞的分离与培养方法 | |
CN106978396A (zh) | 一种脂肪间充质干细胞克隆的扩增培养方法 | |
CN105079783A (zh) | 药物组合物及其制备方法和用途 | |
CN110904033A (zh) | 毛囊干细胞制备方法 | |
CN111956668B (zh) | 一种皮肤再生修复细胞组合物及制备方法 | |
CN111202749A (zh) | 一种具有肌肉细胞修复功能的干细胞活性因子组合物的制备方法 | |
CN111888459A (zh) | 一种含间充质干细胞分泌因子的冻干粉及其溶媒 | |
CN107254431B (zh) | 一种新型组织工程皮肤制备方法 | |
CN107802891A (zh) | 组织工程皮肤及其制备方法 | |
CN101264344B (zh) | 含毛囊人工皮肤的制备方法及由其制备的人工皮肤 | |
CN112546072A (zh) | 一种脂质体包裹人干细胞混悬液的制备方法 | |
CN113957040A (zh) | 一种脂肪干细胞生长因子提取物及其制备方法和应用 | |
CN105925524A (zh) | 一种人原代成纤维细胞转化为表皮细胞的方法 | |
CN111617105A (zh) | 一种脂肪干细胞多细胞活性因子冻干粉的制备方法 | |
CN115651899A (zh) | 一种分离制备脂肪源干细胞的方法 | |
CN108210441A (zh) | 一种用于美容保养的干细胞深层修复精华液 | |
CN113564109A (zh) | 一种经血间充质干细胞的制备方法 | |
CN112587718B (zh) | 利用间充质干细胞分泌的活性因子制备疤痕凝胶的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20221010 Address after: 312000 floor 1 and 3, No. 11, Manchi Road, Gaobu street, Yuecheng District, Shaoxing City, Zhejiang Province Applicant after: Aiketaike (Zhejiang) Holding Co.,Ltd. Address before: Room 508, building C, No.18 JinFang Road, Suzhou Industrial Park, 215000, Jiangsu Province Applicant before: Suzhou beileyong Biotechnology Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210326 |
|
WD01 | Invention patent application deemed withdrawn after publication |